Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Apimeds Pharmaceuticals US Q3 2026 Results: Turns Profitable, Net Income $33.6M

Apimeds Pharmaceuticals US, Inc. reported a net loss of $21.6 million for the nine months ended September 30, 2026, compared to a $4.8 million loss in the prior year. The company transitioned its operations, recording its first software development revenue of $2.48 million while managing a significant digital asset portfolio valued at $142.4 million.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue2.9—
Net income33.6-1.8
EPS (diluted, $ a share)$7.68$-1.42

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Operating margin70.0%
Source

10-Q filed with the SEC, NYSE: APUS. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Apimeds Pharmaceuticals US, Inc.: key numbers

Share price
$1.95Close, Nov 17
Market cap
$3.6M
Shares outstanding
1.85MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Apimeds Pharmaceuticals US, Inc.

All →
9:10 AM ET 8-K
Contract Win

Apimeds Pharmaceuticals US Wins Contract from BlockAssure Inc.

Apimeds subsidiary MindWave Innovations entered into a two-year Master Service Agreement with BlockAssure to build, deploy, and operate AssureChain, a dedicated blockchain subnet for insurance and reinsurance operations. MindWave will receive fixed development fees, future maintenance fees, and a 20% allocation of AssureCoin, a digital token to be created by BlockAssure.

Counterparty
BlockAssure Inc.
Term
2 years
9:15 AM ET 8-K
Leadership Change

Apimeds Pharmaceuticals US Leadership Change

Apimeds Pharmaceuticals US, Inc. appointed Eric Sherb as Chief Financial Officer, effective October 1, 2026, succeeding Erick Frim who resigned as Interim CFO. Mr. Sherb, a CPA with 18 years of experience, will receive an annual base salary of $60,000 under his new employment agreement. The company stated that Mr. Frim's resignation was not due to any disagreements regarding operations, policies, or practices.

4:16 PM ET 8-K
Contract Win

Apimeds Pharmaceuticals US Wins Contract from AQUAE Holdings Pte. Ltd.

Apimeds Pharmaceuticals' subsidiary MindWave Innovations entered into two 12-month technology services agreements to deploy its MindChain blockchain infrastructure. The first agreement with AQUAE Holdings involves powering AQUAEChain for environmental credit management, while the second with Flash Sports & Media involves creating FlashChain for digital broadcasting rights and video assets.

Counterparty
AQUAE Holdings Pte. Ltd. and Flash Sports & Media Holdings, Inc.
Term
12 months
6:02 AM ET 8-K
Reverse Stock Split

Apimeds Pharmaceuticals US Reverse Stock Split

Apimeds Pharmaceuticals US, Inc. implemented a 1-for-10 reverse stock split of its common stock effective July 24, 2026. The split reduced the number of outstanding shares from approximately 15.1 million to 1.5 million and adjusted the par value to $0.001 per share. The company's common stock began trading on a split-adjusted basis on the NYSE American under the symbol 'APUS' at the market open.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.